Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × apalutamide × Head & Neck × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 50 Thoracic 1 Other hematologic neoplasm 1 Head & Neck 1

Conditions

Salivary Gland Neoplasms 1

Interventions

Cisplatin 276 Radiotherapy 122 pembrolizumab 117 Cetuximab 116 Docetaxel 110 Carboplatin 106 Paclitaxel 86 Fluorouracil 85 Radiotherapy, Intensity-Modulated 84 Nivolumab 51 Gemcitabine 45 toripalimab 41 Radiation 40 Capecitabine 36 Drug Therapy 33 Magnetic Resonance Spectroscopy 29 camrelizumab 28 Surgical Procedures, Operative 28 apatinib 26 130-nm albumin-bound paclitaxel 25 tislelizumab 23 Bevacizumab 23 durvalumab 22 Chemoradiotherapy 22 Specimen Handling 21 nimotuzumab 20 Biopsy 19 Albumin-Bound Paclitaxel 19 sintilimab 18 lenvatinib 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04325828 2026-02-13

YATAGARASU

Janssen Pharmaceutical K.K.

Phase 2 Active not recruiting

31 enrolled 15 charts

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡